AstraZeneca completes licensing agreement with LEO Pharma
AstraZeneca has completed a licensing agreement with LEO Pharma, a specialist in dermatology care, for the global licence to monoclonal antibody tralokinumab in skin diseases.
AstraZeneca
11,898.00p
17:15 19/09/24
FTSE 100
8,328.72
16:34 19/09/24
FTSE 350
4,600.84
17:09 19/09/24
FTSE All-Share
4,556.59
16:59 19/09/24
Pharmaceuticals & Biotechnology
22,712.68
17:09 19/09/24
Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115m for the exclusive, global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications.
Tralokinumab is an IL-13 monoclonal antibody that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
AstraZeneca will retain a significant ongoing interest in tralokinumab, so the upfront payment, along with all future commercial milestone and royalty payments, will be reported as externalisation revenue in its financial statements.